The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies
Experimental Eye Research · 2026-09 · 270 · 111133
DOI: 10.1016/j.exer.2026.111133 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Eye Research, 2026-09. Verfasst von Jiehao Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Epithelium, Corneal, Neuroimmunomodulation, Cornea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Dry eye disease (DED) is commonly described through tear-film instability, tear deficiency, evaporative stress, and ocular surface inflammation. These models remain central to diagnosis and treatment, but they do not fully explain symptom-sign discordance, persistent discomfort after surface-directed therapy, epithelial disease with reduced corneal sensation, or variable treatment responses. In this structured narrative review, we synthesize DED-specific, phenotype-specific, adjacent ocular surface, and translational evidence relevant to a bidirectional neuro-immune-epithelial axis involving corneal sensory nerves, trigeminal-parasympathetic reflexes, epithelial and goblet-cell barrier function, and immune-cell activation. Available sensory evidence indicates that corneal sensory abnormalities in DED are heterogeneous: mechanical esthesiometry more often shows reduced sensitivity, whereas non-contact esthesiometry and pain-enriched cohorts may show hypersensitivity or mixed findings. In vivo confocal microscopy (IVCM) studies suggest concurrent changes in corneal nerve morphology and epithelial immune-cell density, but validated thresholds are not sufficient to define a routine neural DED subtype. Neural dysfunction is therefore considered a phenotype-dependent contributor or amplifier, rather than a universal nerve-first mechanism. Treatment implications are discussed according to evidence strength and directness. Varenicline nasal spray and acoltremon engage reflex or sensory tear pathways where approved; motugivatrep illustrates region-specific TRPV1 translation in Japan; diquafosol and rebamipide are epithelial/mucin-supportive therapies with indirect axis relevance; and cenegermin remains primarily a neurotrophic keratitis therapy with restricted relevance to selected DED phenotypes. Neuropeptide-specific targets, availability-limited device stimulation, and direct nerve-regenerative claims for photobiomodulation remain preliminary. This framework may support mechanism-based stratification and rational adjunctive therapy without replacing established DED classifications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
- Department of Ophthalmology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China; Henan Eye Hospital, and Henan Key Laboratory of Ophthalmology and Visual Science, Hena…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., & Li, Z. (2026). The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies. Experimental Eye Research, 270, 111133. https://doi.org/10.1016/j.exer.2026.111133
Vancouver
Zhang J, Li Z. The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies. Experimental Eye Research. 2026;270:111133. doi:10.1016/j.exer.2026.111133
BibTeX
@article{Zhang2026,
author = {Zhang, Jiehao and Li, Zhijie},
title = {The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies},
journal = {Experimental Eye Research},
year = {2026},
volume = {270},
pages = {111133},
doi = {10.1016/j.exer.2026.111133}
}
EUVIMED